Acute Coronary Syndrome - A Pipeline Analysis Report
- Published: Apr 2018
- Pages: 85
- SKU: IRTNTR21783
The 2022-2026 version of this report is just being published. Buy it now and get up to $1000 worth of free customization!
This pipeline analysis report provides detailed insights into the clinical trials landscape of the drug development for acute coronary syndrome including molecules at pre-clinical and over development stages. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as therapy, indications coverage, therapeutic modality, route of administration, mechanism of action, and target.
Overview of the drug development for acute coronary syndrome
Acute coronary syndrome (ACS) impacts the functioning of the heart due to the insufficient supply of blood in the coronary arteries. Atherosclerosis, a buildup of plaque in the coronary arteries, is a major cause of ACS. ACS is consequent in high mortality rates among younger people and in and low and middle-income countries. ACS includes ST-elevation myocardial infarction (STEMI), non-STEMI, and unstable angina. This disease also results in mortality and disability in APAC. Technavio’s market research analysts have predicted that with the introduction of the 12-lead electrocardiogram, as one of the most common diagnostic approaches to treat coronary syndromes, acute coronary syndrome market worth will increase in the forthcoming years.
According to this pipeline analysis report, most of the drug development molecules in the pipeline are in the Phase III development stage and a considerable number of molecules are being evolved for better results.
Acute coronary syndrome market worth: Companies covered
According to the acute coronary syndrome market forecast, this pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug development molecules for acute coronary syndrome. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report
- Dexa Medica
Therapeutic assessment of the drug development pipeline for acute coronary syndrome by route of administration
The intravitreal route of administration (ROA) involves the application of the drug directly onto the vitreous fluid and in the subretinal technique, the molecules are applied to the subretinal space, which will have a more direct effect on the target cells.
Therapeutic assessment of the drug development pipeline for acute coronary syndrome by therapy
- Combination therapy
According to this pipeline analysis report, all the molecules that are currently in the drug development pipeline for acute coronary syndrome are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development for monotherapy.
Key questions answered in the report include
- What are the drug development molecules in the various development stages for acute coronary syndrome?
- What are the companies that are currently involved in the development of drug development for acute coronary syndrome?
- Insight into discontinued/inactive molecules with appropriate reasoning?
- What are the major regulatory authorities approving drugs in various regions?
- Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
PART 05: MAJOR REGULATORY AUTHORITIES
PART 06: PIPELINE LANDSCAPE
PART 07: COMPARATIVE ANALYSIS
- Discovery stage molecules
- Pre-clinical stage molecules
- Inactive and discontinued molecules
PART 08: INDICATION ANALYSIS
PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)
PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)
PART 11: THERAPEUTIC ASSESSMENT BY TARGET
PART 12: KEY COMPANIES
- Active companies: Category and parameters
PART 13: APPENDIX
- List of abbreviations
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
- Market size and forecast
- Market segmentation
- Geographical insights
- Competitive landscape
Get your FREE sample now!
Get the report (PDF) sent to your email within minutes.
Subscribe & Save
Get lifetime access to our
Did you know?
Did you know?
Did you know?
Want to customize this report?
This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.